Drugs / SHAPE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02213861 | Nov 2014 → Oct 2016 | primary cutaneous T-cell lymphoma | TetraLogic Pharmaceuticals | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHAPE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02213861 ↗ |
| Action | Inhibit | “SHAPE, a Histone Deacetylase Inhibitor” NCT02213861 ↗ |
| Route | Topical | “SHAPE administered topically to skin lesions” NCT02213861 ↗ |